Last reviewed · How we verify

NCT04627987: MASTER

Mechanisms of Excess Risk in Aortic Stenosis

Status unknown Last updated 30 April 2021
What this trial tests

trial testing Cardiac MRI scan in Aortic Stenosis in 192 participants. Status unknown.

Timeline
23 March 2021
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorUniversity College, London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment192
Start date23 March 2021
Primary completion1 December 2025
Estimated completion1 December 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University College, London

Who can join

18 and older, any sex, with Aortic Stenosis or Non-Sustained VT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aortic stenosis (AS) is caused by narrowing of one of the main heart valves. Replacing the valve is the only treatment to prevent the heart from failing or death. The timing of replacement is currently often too late - half of patients are left with permanent scarring and a quarter die within 3.5 years. Studies are underway to see if earlier replacement makes a difference. But for those with scarring of the heart, there is currently no tailored treatment. I want to change this by understanding why and how patients with scar are dying and what the investigators can do to prevent this. In this study, the investigators will use a heart scan (MRI) to detect scarring before valve replacement. After replacement, patients will receive a tiny monitor (paper clip size), which the investigators inject underneath the skin. This monitor continuously checks the heartbeat and can detect increased body fluid due to heart failure. The investigators will monitor patients for an average of 3 years to see if scarring is linked to abnormal heart rhythms and heart failure. Once the investigators know how and why, the investigators can target patients with available medications and design studies using specialised treatments, eg defibrillator implantation, to protect patients with scar from dying.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Left Ventricular Hypertrophy in Aortic Stenosis: Early Cell and Matrix Regression 2 Months Post-Aortic Valve Replacement.
    Bennett J, Thornton GD, Nitsche C, Gama FF, et al · · 2024 · cited 5× · PMID 39629586 · DOI 10.1161/circimaging.124.017425
  2. Heart failure and excess mortality after aortic valve replacement in aortic stenosis.
    Aziminia N, Nitsche C, Mravljak R, Bennett J, et al · · 2023 · cited 3× · PMID 36877090 · DOI 10.1080/14779072.2023.2186853

Verify or expand the search:

Other trials of Cardiac MRI scan

Trials testing the same drug.

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04627987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing